In this scenario, given the importance of NHE-1 inhibitors in the treatment of cardiovascular diseases, their usage has been proposed and patented by Florence Porte-Thomé (Geneve, CHF) to treat both acute and long-term cardiovascular complications of SARS-CoV-2 infection such as heart failure, arrythmia, and cardiac ischemia [48]. Here, SLC9A1 is linked to heart failure.